摘要
骨质疏松(ostceporosis)是最常见的骨骼代谢性疾病,其特征包括正常骨密度的减少、骨质脆弱以及骨折的风险性增加。糖皮质激素(glucocorticoids,GCs)治疗的病人容易并发糖皮质激素性骨质疏松症(glucocorticoids-induced osteoporosis,GCOP)。糖皮质激素受体(glucocorticoidreceptor,GR)基因多态性能可改变其受体对糖皮质激素的敏感性,而激素高敏感病人极容易被临床医生所忽视而使用常规剂量糖皮质激素,所以存在更高的糖皮质激素性骨质疏松症风险,甚至出现病理性骨折。糖皮质激素性骨质疏松症最明显的表现为体内的骨代谢水平升高,体内骨代谢敏感性变化能反映骨质疏松的进展情况。然而,近来对糖皮质激素受体基因多态性与骨代谢敏感性的研究缺乏统一的认识。作者对文献进行检索分析发现,糖皮质激素受体基因的多态性可能增强或者减弱其对糖皮质激素敏感性,进而促进或抑制骨代谢,其作用结果和基因多态性位点、受体作用通路等有关。
Osteoporosis is one of the most common bone metabolic diseases, which characters include reduction of normal bone mineral density, and raise of bone fracture risk and fragility. Glucocorticoid-treated pa- tients easily get glucocorticoid-induced osteoporosis. Glucocorticoid receptor gene polymorphisms alter its receptor sensitivity on glucocorticoid. Glucocorticoid high sensitive patients are very likely to be ignored by clinicians when taking of conventional-dose glucocorticoids, so glucocorticoid-induced osteoporosis risk are higher, which may in- clude the pathological fracture. The most obvious manifestation of glucocorticoid-induced osteoporosis is elevation J of the bone metabolism in vivo, and changed bone metabolism sensitivity in vivo reflects the progress of osteoporo- sis. Recently, however, there are lack of a unified understanding of the glucocorticoid receptor gene polymorphism and bone metabolism sensitivity. Our literature search analysis reveals that glucocorticoid receptor gene polymor- phism may enhance or diminish glucocorticoid sensitivity, thereby promoting or inhibiting bone metabolism, and the results may relate with gene polymorphism loci and receptors pathway.
出处
《中国细胞生物学学报》
CAS
CSCD
北大核心
2012年第12期1282-1286,共5页
Chinese Journal of Cell Biology
基金
国家自然科学基金(No.81171748)
浙江省自然科学基金(No.Y2111236)
台州市科技计划A类(No.102KY09)资助项目~~
关键词
糖皮质激素受体
多态性
骨代谢
敏感性
glucocorticoid receptor
polymorphism
bone metabolism
sensitivity
